No description available.

La paroi vasculaire est composée de cellules endothéliales, de cellules musculaires lisses vasculaires et de fibroblastes qui sont entourés d’un réseau structuré et complexe de protéines, la matrice extracellulaire. Les interactions réciproques entre la matrice et les cellules sont nécessaires à la croissance, au développement et au remodelage. Or, différents contextes pathologiques entraînent la perturbation de ces interactions et sont la cause de différentes maladies. Au cours du vieillissement, la matrice extracellulaire des grosses artères élastiques est modifiée. Ainsi, les lamelles élastiques de la paroi vasculaire se fragmentent ou sont dégradées, en plus de calcifier. De même, l’accumulation de protéines plus rigides, comme le collagène, entraîne le développement de la fibrose. Ces modulations vont mener à l’augmentation de la rigidité artérielle et au développement de l’hypertension systolique isolée. En utilisant un modèle animal de calcification basé sur l’inhibition d’une protéine anti-calcifiante, la matrix Gla protein, avec la warfarine, nous avons étudié la séquence des événements impliqués dans le développement de l’hypertension systolique isolée. Nous avons observé l’activation précoce et transitoire de MMP-9, puis du TGF-ß, précédant la modulation phénotypique des cellules musculaires lisses vasculaires, la calcification et les changements hémodynamiques. L’inhibition des métalloprotéinases et du TGF-ß a permis de prévenir la calcification vasculaire. Nous avons également étudié le rôle joué par une enzyme de la matrice extracellulaire, la transglutaminase 2, dans le développement de la calcification associée à l’hypertension systolique isolée. À l’aide d’un nouvel inhibiteur de cette enzyme, qui a permis de prévenir la calcification, nous avons établi que la transglutaminase était un élément clé dans le processus pathologique. Ces travaux ont permis de démontré l’intérêt de nouvelles avenues thérapeutiques ciblant directement la matrice extracellulaire, particulièrement la MMP-9, le TGF-ß et la transglutaminase 2, dans la pathologie de l’hypertension systolique isolée. / Within the vascular wall, endothelial cells, vascular smooth muscle cells and fibroblasts are surrounded by a complex and structured network of secreted macromolecules and proteins, the extracellular matrix. Reciprocal interactions between matrix and cells are essential to growth, development and remodeling. However, in pathological situations, the alteration of these interactions can lead to the development of different disease states. With aging, the extracellular matrix of large elastic arteries undergoes several modifications. The elastic lamellae are fragmented or degraded and calcify, whereas more rigid proteins, such as collagen, accumulate and cause fibrosis. These alterations are associated with the stiffening of arteries, which results in the development of isolated systolic hypertension. In order to study the sequence of events occuring in the development of this pathology, we used an animal model of calcification based on the inhibition of a matrix Gla protein, which physiologically prevents calcification, with warfarin. We observed an acute and transient activation of MMP-9 and TGF-ß, which preceded the phenotypic modulation of vascular smooth muscle cells, calcification and changes to hemodynamic parameters. Moreover, the inhibition of MMPs and TGF-ß prevented vascular calcification. We also studied the role of an extracellular matrix enzyme, transglutaminase 2, in the development of vascular calcification associated with isolated systolic hypertension. Using a novel inhibitor of this enzyme, we established a key role for transglutaminase 2 in this pathological process. This thesis demonstrates the relevance of directly targeting the extracellular matrix, particularly MMP-9, TGF-ß and transglutaminase 2, as a novel therapeutic avenue in the treatment of isolated systolic hypertension.

Introdução: Os lasers fracionados não ablativos são efetivamente utilizados no rejuvenescimento da pele. As novas tecnologias a laser permitem uma remodelação dérmica seletiva, sem ablação da epiderme. Objetivo: Avaliar a eficácia do laser Erbium Glass (Sellas Evo) fracionado não ablativo 1550nm no rejuvenescimento facial através do estudo da quantificação histomorfométrica de fibras colágenas e elásticas, a expressão da molécula de adesão intercelular 1 (ICAM-1) por imuno-histoquímica , a análise das fases do ciclo celular, o potencial elétrico da membrana mitocondrial, a expressão de interleucina-1 (IL-1), o marcador celular endotelial CD34, o receptor do fator transformador de crescimento beta (TGF-beta), atividade da caspase-3 por citometria de fluxo e as alterações ultraestruturais na pele por microscopia eletrônica de varredura, 4 meses após o tratamento com laser. Materiais e Métodos: Quinze indivíduos (média de 56,4 anos, fototipo II-IV), com fotoenvelhecimento cutâneo na face fizeram 3 tratamentos com laser Erbium Glass fracionado não ablativo 1550nm usando uma fluência de 70 mJ e uma densidade de 100 cm2. Foram avaliados biópsias na região pré-auricular em 15 pacientes no início e 4 semanas após o tratamento final. Os níveis de expressão dos receptores e a atividade do potencial elétrico mitocondrial foram analisados na suspensão de células da derme obtida a partir da digestão por colagenase. A avaliação clínica e fotográfica foi analisada quatro semanas após o final do tratamento. Resultados: Após 4 meses do início do tratamento foi observada melhora clínica moderada, com uma média de satisfação de 8,8, as fibras de colágeno aumentaram em 6,68%, as fibras elásticas mostraram uma diminuição de 12,85%, o ICAM-1 aumentou 4,47% significativamente na área dos vasos. Houve aumento significativo dos níveis de expressão do receptor de IL-1 e TGF-beta após o tratamento com laser Erbium Glass. As respostas proliferativas e a ausência de apoptose dependente da caspase-3 foram observadas nas suspensões de células após o tratamento. Conclusão: Rejuvenescimento facial com laser Erbium Glass fracionado não ablativo 1550nm demonstrou melhora visível no fotoenvelhecimento, assim como, aumento significativo da expressão de IL-1 e receptores de TGF-beta, que estão envolvidos na remodelação e indução da proliferação de componentes da matriz extracelular da pele. O grau de satisfação foi alto especialmente em relação à textura, rugas e discromias / Background: Non-ablative fractional lasers have been effectively used in skin rejuvenation. The new laser technologies allow selective dermal remodeling without ablation of the epidermal surface. Objectives: to evaluate the efficacy of the 1550nm Erbium Glass Laser (Sellas Evo) for facial rejuvenation through study of the histomorphometric quantification of colagen and elastic fibers; the expression of intercellular adhesion molecule 1 (ICAM-1) by immnohistochemistry; and analysis of the cell cycle phases, the electrical potential of the mitochondrial membrane and the expression of interleukin 1 (IL-1), the endothelial cell marker CD34 and transforming growth factor beta (TGF-beta) receptors, caspase-3 activity by flow cytometry and the ultrastructural changes in the skin by scanning electron microscopy 4 months after the laser treatment. Materials and methods: fifteen subjects (mean age 56,4 skin typoes II-IV) with photodamage on the face and wrinkles had 3 treatments with the 1550 nm Erbium Glass Laser using a fluence of 70 mJ and a density of 100 cm2. Pre-auricular biopsies from 15 subjects were evaluated at baseline and 4 weeks after the final treatment. Receptor expression levels and the presence of potentially functional mitochondria were analyzed in a cell suspension obtained from collagenase digestion of the skin. Data from the photo assessments and the subjects\' self-assessed improvements were analyzed 4 weeks after the final treatment.Results: Four months after the last treatmenbt application, clinical improvement was observed, with an average satgisfation score of 8.8, corresponding to moderate improvement. After 4 months of treatment, collagen fibers had increased up to 6.68%, while the average proportion of collagen fibers in the dermis, the elastic fibers, showed a 12.85% decrease of ICAM-1 and a mean increase in vessel area of 4.47%.Significantly enhanced IL-1 and TGF-beta receptor expression levels were identified after Erbium Glass Laser treatment. Proliferative responses and non-apoptosis-dependent caspase-3 activity were both observed in the cell suspensions after dermal treatment. Conclusion: Non-ablative rejuvenation with the 1550 mn Erbium Glass Laser was of the IL-1 and TGF-beta receptors, that are involved in remodeling and induced proliferation components in the extracellular matrix of skin fibers. The subjects were highly satisfied, especially regarding texture, rhytids and dyschromia

Mit zunehmender Etablierung der Implantattherapie im zahnärztlichen Alltag stellt die Reduzierung der Einheilzeit durch Oberflächenoptimierung eine der Hauptbestrebungen der forschenden Industrie dar. Dazu treten ästhetische Patientenwünsche nach „weißen“ Materialien, die am ehesten durch das jedoch frakturgefährdete Zirkonmischoxid zu realisieren sind. Ziel der vorliegenden Arbeit war die Untersuchung der Osteokompatibilität verschiedener, metallener Probekörper mit „Zirkoniummischoxidbeschichtung“, in der humanen enoralen Knochenzellkultur. Unter Verwendung einer männlichen Knochenzellkultur über 10 Tage wurden die Expressionen der nonkollagenen Knochenmatrixproteine, Osteocalcin, Osteonectin und Bone Sialo Protein sowie des Wachstumsfaktors TGF-β auf 3 Standardoberflächen und 5 experimentell hergestellten Zirkoniummischoxidoberflächen bestimmt. Es galt zu ermitteln, ob die chemische Zusammensetzung und die Mikrostruktur der getesteten Probekörper Einfluss auf die Proteinexpression haben. Die gewonnenen Versuchsergebnisse lassen vermuten, dass vor allem die Oberflächenkonfigurationen der Experimentaloberflächen 3 (ZSG ½), 4 (ZS4-0,5) und 5 (ZS4-2) die Sekretion o.g. Knochenproteine im Vergleich zu den anderen Experimentaloberflächen sowie dem metallenen Positivstandard (PK7) und dem Negativstandard (PK8) begünstigen. Des Weiteren kann für den als keramischen Positivstandard verwendeten CERCON® Probekörper (PK6) auf Grund der Ergebnisse eine gute biologische Eignung in vitro angenommen werden. Von weiteren Versuchen, welche mit mind. 6 Probekörpern pro Standzeit und Marker durchgeführt werden sollten, lässt sich keine der verwendeten Experimentaloberflächen gerechtfertigt ausschließen.

Le microenvironnement tumoral et les cellules et molécules signal (cytokines et chimiokines) qu’ils contiennent sont reconnus comme jouant un rôle prépondérant dans la progression des tumeurs. Il devient donc nécessaire d’étudier la relation entre les molécules signal, les cellules infiltrantes et les cellules tumorales. Le TGF-β est une puissante cytokine immunosuppressive et suppressive de la croissance cellulaire, dont le rôle dans la formation du microenvironnement tumoral leucémique est mal connu. Dans cette étude, nous avons étudié le modèle injectable de leucémie lymphoïde T EL4 (cellules tumorales produisant du TGF-β) de souche C57BL/6. Nous avons caractérisé l’infiltration de cellules myéloïdes et lymphoïdes au niveau des tumeurs par cytométrie en flux et par microscopie à fluorescence. L’analyse des cellules infiltrant les tumeurs EL4 nous a permis de montrer la forte présence de lymphocytes T et de cellules myéloïdes CD11b+. Nous avons donc poursuivi l’étude afin de mieux caractériser ces cellules. Nous avons montré que ces cellules se retrouvent en périphérie de la tumeur et en périphérie des vaisseaux sanguins de la tumeur. Ces cellules ont des phénotypes nous laissant croire qu’elles appartiennent à la famille des cellules dite myéloïdes suppressives. Ces cellules ont de forts niveaux de transcrits de VEGF et de MMP9 au niveau de la tumeur ainsi qu’au niveau systémique, mais ne semblent pas avoir une forte capacité inhibitrice in vitro. Afin de déterminer si la production tumorale de TGF-β influe le recrutement de ces cellules, nous avons transformé des cellules EL4 à l’aide d’un shRNA afin de diminuer la production de TGF-β (shRNA-TGF-β) et, comparé l’infiltration myéloïde et lymphoïde de tumeurs formées avec des cellules EL4 contrôles (shRNA-Luc). Une diminution de 50% dans les niveaux de transcrits de TGF-β n’affecte pas la croissance tumorale mais semble diminuer l’infiltration par des cellules myéloïdes. La présente étude nous a permis de mieux comprendre le modèle de leucémie EL4 et le rôle des populations cellulaires myéloïdes dans le microenvironnement tumoral leucémique. La diminution du TGF-β produit par les cellules tumorales réduit l’infiltration de ces populations myéloïdes dans la tumeur EL4. Le rôle précis de ces cellules est encore à déterminer. Ces résultats sont en accord avec le fait qu’une thérapie anti-TGF-β n’est pas suffisante pour contrer la progression tumorale, mais pourrait influer sur le résultat post-chimiothérapie et l’immunothérapie en altérant la composition du microenvironnement. / The cells and signal molecules (cytokines and chemokines) making up the tumoral microenvironnement are known to play an essential role in tumor progression. It seems to be necessary to study the relationship between infiltrating cells, tumor cells and signal molecules. TGF-β is a potent immunosuppressive and growth suppressive cytokine whose role in the formation of the leukemia microenvironnement remains unclear. In this study, we investigated the injectable T lymphocyte leukemia EL4 model (tumor cells producing TGF-β) of C57BL/6 strain. We characterised the myeloid and lymphoid infiltration in EL4 tumors using flow cytometry and fluorescence microscopy. Our analysis of EL4 tumor infiltrating cells showed a high concentration of T lymphocytes and myeloid cells CD11b+. We have undertaken our study to better characterize these cells. We showed that these cells are present at the periphery of the tumor and are surrounding blood vessels in the tumor. These cells have phenotypes leading us to believe that they belong to the family of so-called myeloid suppressor cells. They have high levels of transcripts of VEGF and MMP9 in the tumor and the systemic level, but do not seem to have a strong inhibitory capacity in vitro. To determine whether the tumor production of TGF-β affects the recruitment of these cells, we transformed EL4 cells using a shRNA to reduce the production of TGF-β (TGF-β shRNA ) and compared the myeloid and lymphoid infiltration of tumors formed with EL4 cell controls ( shRNA-Luc ) . A 50% decrease in transcript levels of TGF-β does not affect tumor growth but appears to decrease infiltration by myeloid cells. This study allowed us to better understand the pattern of EL4 leukemia and the role of myeloid leukemia cell populations in the tumor microenvironment. The decrease of TGF-β produced by tumor cells reduces the infiltration of these myeloid populations within the EL4 tumor. The precise role of these cells still needs to be determined. These results are in agreement with the fact that anti-TGF-β therapy is not sufficient to counteract tumor progression, but may affect the post-chemotherapy and immunotherapy results by altering the composition of the microenvironment.

Clic proteins influence ethanol-related behavior in flies and other species and also mediate TGF-β signaling. These findings suggest that Clics and the TGF-β signaling pathway might work together to modulate behavioral responses to ethanol. I used the Drosophila model to address the hypothesis that TGF-β signaling is important for ethanol sensitivity. Ethanol sensitivity was blunted by multiple transposon insertions in the TGF-β receptor gene thickveins. Collectively, however, I found no consistent correlation between expression of thickveins and altered ethanol sensitivity in flies harboring transposons. I therefore also assessed ethanol sensitivity in flies with loss of function point mutations in thickveins. Ethanol sensitivity was not altered in these additional thickveins genotypes, contrary to my major hypothesis. My analysis of thickveins suggests that TGF-β signaling might influence ethanol sensitivity, but if so there must be a complex relationship between the function of this pathway and sensitivity to alcohol.

Le phénotype des chondrocytes peut être modulé par des facteurs de croissance comme par des contraintes mécaniques. Nous avons caractérisé le potentiel chondrogénique de la "Bone Morphogenetic Protein" (BMP)-2 sur des chondrocytes murins primaires amplifiés en culture monocouche sur plastique. Nous avons aussi développé un nouveau modèle d’étude de la mécanotransduction par la compression dynamique de ces cellules incluses en hydrogel d’agarose. Nous avons ainsi confirmé l’implication des voies ERK1/2 et p38 dans ces mécanismes, révélé l’activation de Smad2/3 en réponse à la compression et identifié de nouveaux gènes mécano-sensibles. Par ailleurs, nous avons mis en évidence le rôle des intégrines-bêta-1 dans la rigidité du tissu cartilagineux. Nos résultats complètent la connaissance fondamentale des mécanismes de régulation du phénotype chondrocytaire, mais peuvent également contribuer à l'amélioration des techniques de reconstruction du cartilage dans le domaine de l'ingénierie tissulaire. / Chondrocytes phenotype can be modulated by growth factors as well as mechanical stress. We characterised Bone Morphogenetic Protein (BMP)-2 chondrogenic potential on mouse primary chondrocytes expanded in monolayer on culture plastic. Also, we developed a new model to investigate mechanotransduction by applying dynamic compression on these cells embedded in agarose hydrogel. Hence, we confirmed ERK1/2 and p38 pathways implication in such mechanisms, we revealed Smad2/3 activation in response to compression and we identified new mechanosensitive genes. Besides, we highlighted the role of beta-1-integrins in cartilage stiffness. Our results completed the basic knowledge of regulation mechanisms underlying chondrocytes phenotype, but could also contribute to improve techniques for cartilage reconstruction in the field of tissue engineering.

Au sein des tumeurs, y compris pour le carcinome hépatocellulaire (CHC), des sous-populations de cellules néoplasiques ont révélé une grande capacité à initier de nouvelles tumeurs et à induire des métastases. Les premières études sur ces cellules ont rapidement montré que la présence de ces cellules était déterminante dans le développement tumoral et elles ont donc été renommées « cellules souches cancéreuses » (CSCs). Malheureusement les mécanismes impliqués dans la maintenance de ces CSCs ne sont que partiellement compris. Par ailleurs dans le CHC un lien a été établi entre les signaux du facteur de croissance de transformation (Transforming Growth Factor, TGF-ß) provenant du microenvironnement tumoral et certaines populations de cellules cancéreuses dont la présence est corrélée à un faible pronostic. La façon dont TGF-ß peut ainsi établir et modifier un phénotype cellulaire dans le CHC reste néanmoins obscure. La méthylation de l’ADN étant un acteur majeur dans la mise en place des programmes cellulaires, notre but a été de caractériser le méthylome de CSCs hépatiques et son lien avec la capacité de TGF-ß à induire des CSCs. Nous nous sommes appuyés sur l’expression du marqueur CD133 pour définir la population de CSCs hépatiques. Afin comprendre l’importance des marques de méthylation de l’ADN dans les CSCs hépatiques, nous avons dans un premier temps déterminé quelle était la signature des cellules CD133+ au niveau de la méthylation de l’ADN en utilisant des puces de méthylation à grande échelle. Les sites CpG différentiellement méthylés ont montré un enrichissement pour d’une part des voies de signalisation déjà identifiées dans les CSCs et, d’autre part, pour des voies de signalisation associées au processus inflammatoire dont la voie TGF-ß/SMAD. Par la suite, nous avons montré que TGF-ß pouvait induire de façon permanente les cellules CD133+ contrairement à une autre cytokine influente dans le cancer du foie, l’interleukine 6. Cette augmentation de cellules CD133+ induite par TGF-ß est associée à des changements de méthylation de l’ADN sur l’ensemble du génome et qui sont, de plus, maintenus au cours des divisions cellulaires. La comparaison entre les deux méthylomes (liés aux cellules CD133+ et à l’action de TGF-ß) a exposé une signature commune significative indiquant que TGF-ß pourrait promouvoir le phénotype de CSC via le processus de méthylation de l’ADN. Mais nous avons également déterminé qu’une grande partie des effets sur la méthylation induits par TGF-ß était totalement indépendante de l’induction de cellules CD133+. Enfin, nous avons observé que les sites de méthylation sensibles au signal de TGF-ß étaient regroupés de façon significative au niveau de régions « enhancer » qui régulent la transcription des gènes. Par ailleurs, ces sites incluaient également des gènes précédemment identifiés comme cibles de TGF-ß mais aussi des gènes codant pour des acteurs épigénétiques de premier ordre comme les méthyltransférases de l’ADN. Ces résultats constituent la première description d’une signature de méthylation de l’ADN induite par TGF-ß permettant une reprogrammation stable vers un profil épigénétique de CSC hépatiques. / Distinct subpopulations of neoplastic cells within tumors, including hepatocellular carcinoma (HCC), display a pronounced ability to initiate new tumors and induce metastasis. Investigations on theses cells rapidly described them as essential for tumor growth and based on theses observations they have been named “cancer stem cells” (CSCs). Unfortunately, the mechanisms involved in sustaining their programs are only partially known. In HCC, there is an established link between microenvironmental signals from Transforming Growth Factor beta (TGF-ß) and survival of certain cell subpopulations which is results in a bad prognosis. However, how TGF-ß establishes and modifies cell behavior in HCC is not fully understood. As DNA methylation is involved in establishing cellular programs, our aim was to characterize the methylome of putative liver CSCs, and its link to the ability of TGF-ß to induce liver CSCs. We used CD133 expression as a positive marker for liver CSC. To understand the relevance of DNA methylation programs in liver CSCs, we first defined the methylome signature of CD133+ cells in liver cancer cells using methylation bead arrays. Differentially methylated CpG sites were enriched in known pathways related to CSC survival and to inflammation, including the TGF-ß/SMAD pathway. Next, we showed that TGF-ß persistently induces CD133+ cells in opposition to another cytokine related to HCC, interleukin 6. We observed that this increase is associated with genome-wide changes in the methylome induced by TGF-ß and that are perpetuated through cell division. We observed a significant overlap between the CD133+ methylome and the methylome induced by TGF-β, indicating that TGF-ß may induce CSC phenotype through DNA methylation reprogramming. Additionally, we observed genome-wide effects of TGF-ß that are independent of the induction of CD133. Finally, TGF-ß methyl-sensitive sites were significantly concentrated in enhancer regions of the genome, and include well-known targets of TGF-ß, and epigenetic players, such as de novo DNA methyl-transferases. In conclusion our results are the first indication of the ability of TGF-ß to induce genome-wide changes of DNA methylation, leading to a stable switch to a liver cancer stem cell epigenetic program.

Myostatin is a secreted growth factor of the transforming growth-factor $\beta$ (TGF$\beta$) superfamily, and a powerful negative regulator of muscle mass in vertebrates. As such, there is considerable interest in developing pharmacological agents which inhibit myostatin signalling in order to stimulate muscle growth in the context of pathological muscle wasting. Like other TGF$\beta$ family proteins, myostatin is biosynthesised as an inactive (latent) precursor protein which requires proteolytic processing to liberate the mature bioactive growth factor. To examine the molecular basis of pro-myostatin latency and the mechanism by which it is activated in the extracellular space, I have determined the crystal structure of unprocessed human pro-myostatin and studied the properties of the protein at various stages of activation. Crystallographic analysis of pro-myostatin reveals a unique domain-swapped dimeric structure, with an open V-shaped conformation distinct from the prototypical family member, TGF$\beta$1. Following cleavage of the prodomains by furin, pro-myostatin persists as a stable non-covalent complex which is resistant to the natural inhibitor follistatin and exhibits significantly weaker bioactivity than the mature growth factor. A number of distinct structural features combine to stabilise the interaction between pro and mature domains and in doing so confer latency to the pro-complex. This facilitates a controlled, step-wise process of activation in the extracellular space and contributes to a complex network of regulatory control. The results presented here provide a structural basis for understanding the effect of natural polymorphisms on myostatin function and a starting point for structure-guided development of next generation myostatin inhibitors. As a proof-of-concept, I present preliminary data on prodomain derived stapled peptides as inhibitors of myostatin signalling.

A new model of a critically-sized segmental femoral bone defect in rats was developed to enable in vivo imaging and facilitate post-mortem mechanical testing of samples. The critically-sized nature of the model was assessed and confirmed. The efficacy of sustained co-delivery of osteogenic (BMP-2 and TGF- Ò3) and angiogenic (VEGF) growth factors in promoting functional bone repair was assessed. Effects of scaffold modification in terms of geometry and composition were evaluated. The results indicated that co-delivery of BMP-2 and TGF- Ò3 resulted in a dose-dependent improvement in functional bone repair. Modification of the polylactide scaffold to include an absorbable ceramic component and a cored out geometry enhanced rate of union. Addition of VEGF to the scaffold treatment did not significantly impact revascularization of the defect site or functional repair of the bone defect. These data demonstrate that the complex environment of an acute bone defect requires different treatment strategies than simple ectopic models would suggest. A positive predictive correlation between bone repair parameters measured in vivo and mechanical functionality was established. The novel defect model demonstrated robustness and reproducibility. Implications for further research are discussed.